Seeking Alpha

Encouraging preliminary results for MEI's cancer drug

  • Preliminary results from a Phase 2a clinical trial of MEI Pharmaceuticals' (MEIP +16.4%) histone deacetylase (HDAC) inhibitor Pracinostat in combination with Vidaza (azacitidine) as a treatment for acute myeloid leukemia in elderly patients unsuitable for intensive chemotherapy suggest some patients would benefit greatly from the regimen. Of the first nine participants, two achieved a complete response and one achieved a complete response with incomplete blood count recovery after one or two treatment cycles. Three additional patients achieved either a partial response or partial response with incomplete blood count recovery.
  • The results met the pre-specified response rate allowing investigators to proceed to the Phase 2b stage.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|